Cytokine and chemokine profiles in neuromyelitis optica: Significance of interleukin-6

Multiple Sclerosis

Volumn 16, Issue 12, 2010, Pages 1443-1452

  Uzawa, Akiyuki ^a   Mori, Masahiro ^a   Arai, Kimihito ^b   Sato, Yasunori ^c   Hayakawa, Sei ^a   Masuda, Saeko ^a   Taniguchi, Junko ^a   Kuwabara, Satoshi ^a  

^a CHIBA UNIVERSITY   (Japan)

^b SAKURA NATIONAL HOSPITAL   (Japan)

^c CHIBA UNIVERSITY HOSPITAL   (Japan)

Author keywords

chemokine; cytokine; glial fibrillary acidic protein; immunohistochemical staining; interleukin 6; multiple sclerosis; neuromyelitis optica

Indexed keywords

AQUAPORIN 4; BASIC FIBROBLAST GROWTH FACTOR; CHEMOKINE; CYTOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLIAL FIBRILLARY ACIDIC PROTEIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 6; INTERLEUKIN 8; INTERLEUKIN 9; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIBODY TITER; ARTICLE; BLOOD LEVEL; CEREBROSPINAL FLUID LEVEL; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; IMMUNE SYSTEM; IMMUNOHISTOCHEMISTRY; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NEUROLOGIC DISEASE; PATHOGENESIS; RELAPSE; SERUM; TH17 CELL;

ADULT; AGED; CHEMOKINES; CYTOKINES; FEMALE; HUMANS; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-6; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROMYELITIS OPTICA;

EID: 78650092261     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458510379247     Document Type: Article

References (40)

1. Wingerchuk DM, Hogancamp WF, O'Brien PC and Weinshenker BG The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999 ; 53: 1107 1114.
2. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ and Weinshenker BG The spectrum of neuromyelitis optica. Lancet Neurol 2007 ; 6: 805 815.
3. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS and Hinson SR IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005 ; 202: 473 477.
4. Takahashi T., Fujihara K., Nakashima I., Misu T., Miyazawa I., Nakamura M., et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain 2007 ; 130: 1235 1243.
5. Roemer SF, Parisi JE, Lennon VA, Benarroch EE, Lassmann H., Bruck W., et al. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 2007 ; 130: 1194 1205.
6. Misu T., Fujihara K., Kakita A., Konno H., Nakamura M., Watanabe S., et al. Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain 2007 ; 130: 1224 1234.
7. Ito S., Mori M., Makino T., Hayakawa S. and Kuwabara S. ''Cloud-like enhancement'' is a magnetic resonance imaging abnormality specific to neuromyelitis optica. Ann Neurol 2009 ; 66: 425 428.
8. Matsuoka T., Matsushita T., Kawano Y., Osoegawa M., Ochi H., Ishizu T., et al. Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese. Brain 2007 ; 130: 1206 1223.
9. Uzawa A., Mori M., Hayakawa S., Masuda S. and Kuwabara S. Different responses to interferon beta-1b treatment in patients with neuromyelitis optica and multiple sclerosis. Eur J Neurol 2010 ; 17: 672 676.
10. Lucchinetti CF, Mandler RN, McGavern D., Bruck W., Gleich G., Ransohoff RM, et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002 ; 125: 1450 1461.
11. Luster AD Chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med 1998 ; 338: 436 445.
12. Sharief MK and Hentges R. Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N Engl J Med 1991 ; 325: 467 472.
13. Sharief MK and Thompson EJ Correlation of interleukin-2 and soluble interleukin-2 receptor with clinical activity of multiple sclerosis. J Neurol Neurosurg Psychiatry 1993 ; 56: 169 174.
14. Link J., Soderstrom M., Olsson T., Hojeberg B., Ljungdahl A. and Link H. Increased transforming growth factor-beta, interleukin-4, and interferon-gamma in multiple sclerosis. Ann Neurol 1994 ; 36: 379 386.
15. van Boxel-Dezaire AH, Hoff SC, van Oosten BW, Verweij CL, Drager AM, Ader HJ, et al. Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis. Ann Neurol 1999 ; 45: 695 703.
16. Franciotta D., Martino G., Zardini E., Furlan R., Bergamaschi R., Andreoni L., et al. Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapies. J Neuroimmunol 2001 ; 115: 192 198.
17. Narikawa K., Misu T., Fujihara K., Nakashima I., Sato S. and Itoyama Y. CSF chemokine levels in relapsing neuromyelitis optica and multiple sclerosis. J Neuroimmunol 2004 ; 149: 182 186.
18. Ishizu T., Osoegawa M., Mei FJ, Kikuchi H., Tanaka M., Takakura Y., et al. Intrathecal activation of the IL-17/ IL-8 axis in opticospinal multiple sclerosis. Brain 2005 ; 128: 988 1002.
19. Matusevicius D., Kivisäkk P., He B., Kostulas N., Ozenci V., Fredrikson S., et al. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler 1999 ; 5: 101 104.
20. Lock C., Hermans G., Pedotti R., Brendolan A., Schadt E., Garren H., et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 2002 ; 8: 500 508.
21. Tanaka M., Matsushita T., Tateishi T., Ochi H., Kawano Y., Mei FJ, et al. Distinct CSF cytokine/chemokine profiles in atopic myelitis and other causes of myelitis. Neurology 2008 ; 71: 974 981.
22. Yanagawa K., Kawachi I., Toyoshima Y., Yokoseki A., Arakawa M., Hasegawa A., et al. Pathologic and immunologic profiles of a limited form of neuromyelitis optica with myelitis. Neurology 2009 ; 73: 1628 1637.
23. Uzawa A., Mori M., Ito M., Uchida T., Hayakawa S., Masuda S., et al. Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis. J Neurol 2009 ; 256: 2082 2084.
24. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF and Weinshenker BG Revised diagnostic criteria for neuromyelitis optica. Neurology 2006 ; 66: 1485 1489.
25. Hayakawa S., Mori M., Okuta A., Kamegawa A., Fujiyoshi Y., Mitsuoka K., et al. Neuromyelitis optica and anti-aquaporin-4 antibodies measured by an enzyme-linked immunosorbent assay. J Neuroimmunol 2008 ; 196: 181 187.
26. McDonald WI, Compston A., Edan G., Goodkin D., Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001 ; 50: 121 127.
27. Correale J. and Fiol M. Activation of humoral immunity and eosinophils in neuromyelitis optica. Neurology 2004 ; 63: 2363 2370.
28. Weaver CT, Hatton RD, Mangan PR and Harrington LE IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 2007 ; 25: 821 852.
29. Onishi RM and Gaffen SL Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology 2010 ; 129: 311 321.
30. Wang GY, Sun B., Kong QF, Zhang Y., Li R., Wang JH, et al. IL-17 eliminates the therapeutic effects of myelin basic protein-induced nasal tolerance in experimental autoimmune encephalomyelitis by activating IL-6. Scand J Immunol 2008 ; 68: 89 97.
31. Iwakura Y. and Ishigame H. The IL-23/IL-17 axis in inflammation. J Clin Invest 2006 ; 116: 1218 1222.
32. Fossiez F., Djossou O., Chomarat P., Flores-Romo L., Ait-Yahia S., Maat C., et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med 1996 ; 183: 2593 2603.
33. Van Wagoner NJ, Oh JW, Repovic P. and Benveniste EN Interleukin-6 (IL-6) production by astrocytes: autocrine regulation by IL-6 and the soluble IL-6 receptor. J Neurosci 1999 ; 19: 5236 5244.
34. Misu T., Takano R., Fujihara KT, Takahashi T., Sato S. and Itoyama Y. Marked increase in cerebrospinal fluid glial fibrillar acidic protein in neuromyelitis optica: an astrocytic damage marker. J Neurol Neurosurg Psychiatry 2009 ; 80: 575 577.
35. Lee HK, Seo IA, Suh DJ, Hong JI, Yoo YH and Park HT Interleukin-6 is required for the early induction of glial fibrillary acidic protein in Schwann cells during Wallerian degeneration. J Neurochem 2009 ; 108: 776 786.
36. Jarius S., Aboul-Enein F., Waters P., Kuenz B., Hauser A., Berger T., et al. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain 2008 ; 131: 3072 3080.
37. Quintana A., Muller M., Frausto RF, Ramos R., Getts DR, Sanz E., et al. Site-specific production of IL-6 in the central nervous system retargets and enhances the inflammatory response in experimental autoimmune encephalomyelitis. J Immunol 2009 ; 183: 2079 2088.
38. Eugster HP, Frei K., Kopf M., Lassmann H. and Fontana A. IL-6-deficient mice resist myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. Eur J Immunol 1998 ; 28: 2178 2187.
39. Linker RA, Lühder F., Kallen KJ, Lee DH, Engelhardt B., Rose-John S., et al. IL-6 transsignalling modulates the early effector phase of EAE and targets the blood brain barrier. J Neuroimmunol 2008 ; 205: 64 72.
40. Kaplin AI, Deshpande DM, Scott E., Krishnan C., Carmen JS, Shats I., et al. IL-6 induces regionally selective spinal cord injury in patients with the neuroinflammatory disorder transverse myelitis. J Clin Invest 2005 ; 115: 2731 2741.